Harrow Health (HROW) Issues Quarterly Earnings Results

Share on StockTwits

Harrow Health (NASDAQ:HROW) posted its quarterly earnings results on Tuesday. The company reported $0.77 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.07), Fidelity Earnings reports. The firm had revenue of $11.38 million during the quarter, compared to analyst estimates of $10.92 million. Harrow Health had a negative net margin of 16.81% and a negative return on equity of 231.16%.

Shares of HROW traded down $0.92 during mid-day trading on Thursday, reaching $5.13. The company had a trading volume of 457,534 shares, compared to its average volume of 213,687. Harrow Health has a twelve month low of $1.71 and a twelve month high of $7.20. The company has a current ratio of 1.13, a quick ratio of 0.88 and a debt-to-equity ratio of 2.84. The stock has a market cap of $158.52 million, a PE ratio of -8.55 and a beta of 0.07.

Separately, Zacks Investment Research cut Harrow Health from a “hold” rating to a “sell” rating in a report on Wednesday.

In other news, Director Robert J. Kammer sold 10,000 shares of the stock in a transaction that occurred on Friday, February 1st. The stock was sold at an average price of $5.86, for a total value of $58,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 13.78% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Harrow Health (HROW) Issues Quarterly Earnings Results” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/4221070/harrow-health-hrow-issues-quarterly-earnings-results.html.

Harrow Health Company Profile

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Further Reading: What is cost of equity?

Earnings History for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Zacks: Vector Group Ltd  Receives Consensus Recommendation of “Hold” from Brokerages
Zacks: Vector Group Ltd Receives Consensus Recommendation of “Hold” from Brokerages
Zacks: Analysts Anticipate Masimo Co.  Will Announce Earnings of $0.75 Per Share
Zacks: Analysts Anticipate Masimo Co. Will Announce Earnings of $0.75 Per Share
EtherSportz Hits Market Capitalization of $162,386.00
EtherSportz Hits Market Capitalization of $162,386.00
Cybereits Price Reaches $0.0014 on Exchanges
Cybereits Price Reaches $0.0014 on Exchanges
Zacks: Analysts Anticipate First Community Co.  Will Announce Quarterly Sales of $11.76 Million
Zacks: Analysts Anticipate First Community Co. Will Announce Quarterly Sales of $11.76 Million
VICI Properties Inc  Expected to Announce Quarterly Sales of $219.49 Million
VICI Properties Inc Expected to Announce Quarterly Sales of $219.49 Million


© 2006-2019 Ticker Report